Will You Still Be Able to Get Compounded Semaglutide?

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Recent regulatory scrutiny has raised questions about the future of compounded semaglutide, but access remains stable for qualified patients seeking this treatment. The FDA distinguishes between licensed 503A compounding pharmacies—which operate under strict quality standards—and 503B outsourcing facilities, a critical distinction that protects patient safety and treatment continuity.

Why Compounded Semaglutide Remains Legal and Available

Compounded medications have existed in U.S. healthcare for decades under the Pharmacy Compounding Accreditation Board (PCAB) framework. Licensed 503A compounding pharmacies operate within federal law when they prepare individualized doses for specific patients with valid prescriptions. This differs fundamentally from 503B outsourcing facilities, which manufacture bulk medications without patient-specific orders and face stricter FDA oversight.

PlexusDx sources compounded semaglutide exclusively from licensed 503A pharmacies that meet rigorous quality, sterility, and potency standards. The regulatory environment continues to support this model for compounds addressing unmet patient needs. Compounded semaglutide remains an appropriate option when prescribed by a licensed healthcare provider for weight management in eligible patients.

The distinction between 503A and 503B operations is central to understanding why compounded semaglutide availability is not in jeopardy. 503A compounders serve a critical role in personalized medicine, allowing dosing and formulation customization impossible with mass-manufactured products. This regulatory pathway protects both patient access and pharmacovigilance.

How PlexusDx Ensures Safe, Compliant Semaglutide Delivery

PlexusDx partners exclusively with licensed 503A compounding pharmacies that maintain accreditation and undergo routine quality audits. Every batch of compounded semaglutide is formulated under strict pharmaceutical standards before shipment to patients. This commitment to compliance means patients receive medications with verified strength, purity, and sterility—not the inconsistent products sometimes associated with unregulated suppliers.

Patient safety is the foundation of PlexusDx's supply chain. All prescriptions require evaluation by a licensed physician who assesses medical history, current medications, and weight loss goals before compounding begins. This personalized gatekeeping ensures only suitable candidates receive semaglutide injections, reducing adverse event risk compared to non-medical purchasing.

PlexusDx's nationwide network of 503A partners allows consistent access across all 50 states without membership fees or insurance requirements. Patients maintain the same pricing—at $189/mo month-to-month, or from $149/mo on the 6-month plan for compounded semaglutide injection—regardless of their dose level, because your dose may need to go up but your price won't.

Regulatory Trends Supporting Compounded GLP-1 Therapy

The FDA has issued guidance emphasizing that 503A compounding serves legitimate medical needs when branded alternatives are unavailable, discontinued, or unsuitable for a patient's clinical situation. Semaglutide availability through compounding addresses real access barriers, including cost, supply disruptions, and individual dosing requirements. This regulatory environment remains stable because compounding fills a genuine gap in the healthcare system.

State pharmacy boards, which license and oversee 503A compounders, continue to support this model within their jurisdictions. Recent regulatory actions have focused on fraudulent operators and 503B facilities making false FDA claims—not on legitimate 503A compounders serving prescribed patients. PlexusDx's compliance with state and federal pharmacy laws ensures long-term access for its patient community.

Insurance coverage gaps and manufacturer supply constraints have reinforced the role of compounding in modern weight loss medicine. Rather than restricting access, regulators recognize that licensed compounders help patients access GLP-1 therapy when other pathways fail. This clinical rationale supports continued availability of compounded semaglutide through compliant channels.

Personalization Through Precision Peptide Genetic Testing

Beyond regulatory compliance, PlexusDx differentiates its semaglutide offering through the Precision Peptide Genetic Test—a peptide-pathway genetic assessment that describes the pathway-level variants involved. This $298 test maps 14 metabolic pathways, 49 peptides, and 150+ genetic insights, including key variants like GIPR rs1800437 that influence semaglutide efficacy.

Genetic predispositions to semaglutide response help patients and providers choose the right compound from the outset. Some individuals show stronger response markers to semaglutide injection alone, while others may benefit from PlexusDx's GLP-Squared formula combining semaglutide and tirzepatide. This precision approach enhances outcomes and justifies the upfront investment in genetic insights, with tests available after the first month of treatment.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide legal and safe to use in 2024?

Yes. Compounded semaglutide prepared by licensed 503A pharmacies remains legal when prescribed by a healthcare provider. PlexusDx sources exclusively from accredited 503A compounders meeting strict quality and sterility standards. Patient safety is protected through physician evaluation and verified pharmaceutical compounding practices.

What is the difference between 503A and 503B compounding?

503A compounders prepare individualized medications for specific patients with valid prescriptions in a regulated pharmacy setting. 503B outsourcing facilities manufacture bulk medications without patient-specific orders and face direct FDA oversight. PlexusDx uses only 503A compounders, which operate within established legal frameworks for personalized medicine.

How much does compounded semaglutide cost at PlexusDx?

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) and remains flat regardless of your dose level. HSA and FSA accounts are eligible for payment, and no insurance or membership fee is required. Access is available across all 50 states with transparent, predictable pricing.

Will PlexusDx still be able to provide compounded semaglutide in the future?

PlexusDx's partnership with licensed 503A compounding pharmacies provides long-term stability. Regulatory support for legitimate 503A compounding remains strong, especially when addressing patient access barriers. PlexusDx's compliance-first model and nationwide network ensure continued availability.

How does the Precision Peptide Genetic Test improve semaglutide outcomes?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR (rs1800437)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Compounded Semaglutide 2
• Compounded Semaglutide
• Medvi Semaglutide
• Bioverse Semaglutide

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.